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In 2019, an outbreak of an unknown coronavirus – SARS-CoV-2 – responsible for
COVID-19 disease, was first reported in China, and evolved into a pandemic of huge
dimensions and raised serious concerns for global health. The number of critical cases
continues to increase dramatically, while vaccines and specific treatments are not
yet available. There are several strategies currently being studied for the treatment
of adverse symptoms of COVID-19, that encompass Acute Lung Injury (ALI)/Acute
Respiratory Distress Syndrome (ARDS), extensive pulmonary inflammation, cytokine
storm, and pulmonary edema, due to virus-induced pneumonia. Mesenchymal stem
cells (MSCs) are at the origin of new revolutionary treatments, which may come to be
applied in such as Regenerative Medicine, Immunotherapy, Tissue Engineering, and
Cell and Molecular Biology due to immunomodulation and anti-inflammatory activity.
MSCs have already been studied with positive outcomes for other lung pathologies,
thus representing and being identified as an important opportunity for the treatment
of COVID-19. It has recently been shown that these cells allow hopeful and effective
therapies for serious or critical COVID-19, minimizing its adverse symptoms. In this study
we will analyze the MSCs, their origin, differentiation, and therapeutic potential, making
a bridge with the COVID-19 disease and its characteristics, as a potential therapeutic
strategy but also reporting recent studies where these cell-based therapies were used
for the treatment of COVID-19 patients.
Keywords: cell-based therapies, secretome, mesenchymal stem cells, coronavirus, SARS-CoV-2
Abbreviations: AF, amniotic fluid; ALI, acute lung injury; ARSD, acute respiratory distress syndrome; AT, adipose tissue; AT-
MSCs, adipose tissue mesenchymal stem cells; BM, bone marrow; BM-MSCs, bone marrow mesenchymal stem cells; CFU-F,
colony forming unit-fibroblast; DP, dental pulp; DP-MSCs, dental pulp mesenchymal stem cells; EVs, extracellular vesicles;
GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth factor; ISCT, The International
Society for Cellular Therapy; MERS, middle east respiratory syndrome; MHC, major histocompatibility complex; MSCs,
mesenchymal stem cells; OM-MSCs, olfactory mucosa mesenchymal stem/stromal cells; SARS, Severe Acute Respiratory
Syndrome; TMPRSS2, transmembrane protease serine-2; UCB, umbilical cord blood; UCB-MSCs, umbilical cord blood
mesenchymal stem cells; UCT, umbilical cord tissue; UC-MSCs, umbilical cord mesenchymal stem cells; WJ, Wharton’s Jelly;
WJ-MSCs, Wharton’s Jelly mesenchymal stem cells.
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INTRODUCTION
Since the end of 2019 that a series of unexplained cases of
pneumonia caused by an unknown virus were reported in
Wuhan, China. The research began and on 12 January 2020, when
the World Health Organization (WHO) identified the newly
discovered virus as the “2019 Novel Coronavirus” (2019-nCoV),
formally naming the infection as Coronavirus Disease 2019 –
COVID-19 – on 30 January. On the same day, the International
Committee on Taxonomy of Viruses identified the 2019-nCoV as
a Severe Acute Respiratory Syndrome 2 – SARS-CoV-2 (Sun et al.,
2020b). First outbreak reported in China, this disease quickly
spread to all continents mainly due to international flights,
becoming a pandemic recognize by the WHO since January 2020,
affecting nowadays 213 countries and territories, with more than
11 million active cases and more than half a million deaths,
representing a serious global public health emergency (Table 1)
(Worldometer, 2020).
SARS-CoV-2 is characterized as a coronavirus, belonging
to the cluster of β−coronavirus. COVID-19 appears as the
third zoonotic disease caused by this type of virus, after Severe
Acute Respiratory Syndrome (SARS) and the Middle East
Respiratory Syndrome (MERS). The first cases identified as
COVID-19 were related to the Huanan seafood market, since
environmental samples were collected from the seafood market,
and consequently, it is believed that SARS-CoV-2 mutated and
an intermediate host that infected the patient zero in the market
allowed the interspecies transmission to humans (Li et al.,
2020b). Although it has not been possible to determine with
certainty whether a particular specie carries the SARS-CoV-
2, studies demonstrated that SARS−CoV−2 was a chimeric
virus that originated from a bat coronavirus and another one
of undetermined origin. As a well-known natural reservoir for
α-coronavirus and β-coronavirus, bats are carriers of distinct
SARS-like-CoVs (Sun et al., 2020a). Therefore, various researches
reinforced the hypothesis that the transmission chain originated
from animals (bats) to humans.
Structure and Mechanism of
SARS-CoV-2
Coronaviruses, or Orthocoronavirinae, are enveloped, positive,
single−stranded large RNA viruses that researchers previously
thought that transmitted disease only to animals until the
world witnessed the SARS epidemic outbreak caused by SARS-
CoV in 2002. Currently are known 7 CoVs (SARS-CoV-2
included) responsible for causing human respiratory illnesses,
although only SARS-CoV-2, MERS-CoV, and SARS-CoV have
been associated with outbreaks with high infection rate and
high mortality (Li et al., 2020a). Coronavirus dimensions can
vary from 26 to 32 kb in length, 60–140 nm in diameter, with
peptameric spiky projections on its external surface, looking as
crown like spikes under the electron microscopy (Madabhavi
et al., 2020). The spike protein is mainly responsible for the
occurrence of cell tropism and inter-species transmission, since
it allows the virus to bind to a cell receptor and its subsequent
penetration into the cell through its membrane. Researchers
discovered that angiotensin−converting enzyme 2 (ACE-2) is
the receptor for SARS−CoV−2 (Madabhavi et al., 2020; Sun
et al., 2020a) in healthy human lung, being expressed on alveolar
epithelial cells type I and II. The attachment of SARS−CoV−2
to ACE-2 leads to an elevation of the expression of ACE-2,
that can trigger injures on alveolar cells. Sequentially, these
lesions can promote severe systemic reactions and culminate
in death. ACE-2 is expressed in other tissues such as the
kidney, liver, heart and other organs, this expression being
the reason behind critical patients suffering not only from
respiratory complications, but multiple organ dysfunction as well
(Sun et al., 2020b). The nasal epithelium was found the first
site of infection but also in transmission among patients, with
symptomatic but also asymptomatic clinical spectrum (Xiao et al.,
2020). Like it is observed in other SARS-CoV infections, the S
protein of SARS-CoV-2 is able to bind the ACE-2 which allows
the cell entering catalyzed by transmembrane protease serine-
2 (TMPRSS2) protease mostly in type II alveolar cells in the




As of October 6, 2020, the total number of confirmed cases
was 35,736,102, including 1,046,546 deaths in all five continents,
and a total of 26,894,740 recovered patients (Worldometer,
2020), nowadays a second vague of infection is being observed
worldwide (Table 1). All ages are vulnerable to this lethal virus
infection, and its transmission is made in the course of coughing
and sneezing, through infected droplets by infected patients, able
to spread about 1–2 m and deposit on surfaces. One of the
main factors of the high rate of transmission of this virus is
the fact that can also occur from asymptomatic people before
the start of symptoms. The incubation period varies from 2
to 14 days. The first studies about COVID-19 transmission
profile revealed that the basic reproductive number (R0) of 2019-
nCoV is positioned between 1.4 and 3.9 (Bulut and Kato, 2020).
Researchers also noticed a 3.25:1 ratio of male to female deaths, a
fact probably related to the higher numbers of ACE-2 receptors
present in male alveoli. The age range of deaths by COVID-
19 was 70 years or older, although the deaths of younger age
groups are now increasing. Findings made so far indicate that
the progression of the disease is faster in older individuals,
especially on those who have comorbidities, than in the young
(Sun et al., 2020b).
COVID-19 can be clinically divided in five groups:
asymptomatic, mild, moderate, severe, and critical. The
symptoms of these categories vary, with asymptomatic having
no symptoms with a positive SARS-CoV-2 PCR test. The
mild group manifests itself through signs such as fever,
myalgia, cough, fatigue, sore throat, and sneezing, runny
nose without evolution to pneumonia, basically signs of acute
upper respiratory tract infection. More aggressive symptoms
such as fever, cough and pneumonia with no indication of
shortness of breath or hypoxemia should be included in the
moderate group. The severe group includes cases of rapid
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TABLE 1 | Total confirmed cases, total deaths, and total cases per 1M population
of the 10 countries most affected by COVID-19, and the data from Portugal for
comparison (Data consulted on October 10 at worldometers.info/coronavirus)
(Worldometer, 2020).
Country Total Cases Total Deaths Total cases/1M pop
United States 7,895,738 218,685 23,816
India 6,979,423 107,450 5,044
Brazil 5,057,190 149,692 23,746
Russia 1,285,084 22,454 8,805
Colombia 894,300 27,495 17,525
Spain 890,367 32,929 19,041
Argentina 871,468 23,225 19,234
Peru 843,355 33,158 25,482
Mexico 809,751 83,507 6,262
France 691,977 32,583 11,567
Portugal (49th) 83,928 2,062 8,238
evolution (in most cases in 1 week), where oxygen saturation
below 92% promotes signs of central cyanosis, dyspnea and
other symptoms of hypoxemia. Finally, the critical patients
present acute ARDS or respiratory failure with multiple
organ dysfunction, requiring mechanical ventilation and life
support (Bulut and Kato, 2020). The main pathologic traits
for COVID-19 patients in the severe or critical groups include
the development of extensive pulmonary edema, pulmonary
inflammation, diffuse alveolar damage with cellular fibromyxoid
exudates, hyaline membrane formation and hypoxemia. Even
though the pathologic alterations are similar to ALI/ARDS,
also witnessed in MERS and SARS coronavirus infections,
more serious phenomena of inflammatory cytokine storm,
severe inflammatory exudation, milder pulmonary fibrosis and
consolidation, pulmonary edema and serious inflammatory
exudation were observed in severe or critical COVID-19
(Liu et al., 2020). The severe and critical patients will have
long-term health impact of COVID-19. Taken all together,
MSCs-based therapy seems to be a possible strategy for patients’
treatment and rehabilitation, mostly what concerns pulmonary
parenchyma regeneration.
Prevention and Treatment of COVID-19
At the date of October 2020, there is not yet a vaccine
against COVID-19 available. The vaccine is considered as an
effective prophylactic strategy for control and prevention, and
is being researched and developed in about 90 institutions
worldwide. The knowledge of the structure of the SARS-
COV-2 spike protein (S) should enable rapid evaluation and
further studies to optimize vaccination strategies. Several possible
treatments are also being studied, some of them were already
considered ineffective for COVID-19, such as chloroquine and
hydroxychloroquine. The multiple treatment strategies include
antiviral agents like Remdesivir designed for Ebola treatment,
drugs routinely used to treat autoimmune diseases and malaria
which drew attention for their potential as broad-spectrum
antiviral drugs; corticosteroids to suppress lung inflammation;
several immunotherapies; convalescent plasmas transfusion.
Finally, new therapies like blocking agents that present affinity to
bind to ACE2 receptor and the use of cell-based approaches such
as MSCs, have been studied and tested as potential approaches
(Zhai et al., 2020).
The currently available treatment to COVID-19 depends
basically on the patients’ immune system. COVID-19 can trigger
a destroying immune overreaction, contributing to the worsening
of the disease. When the immune system is activated in a
reactive way, the physiological mechanisms of containment of the
virus trigger the production and release of several inflammatory
mediators, resulting in a severe cascade of cytokines. This
mechanism can culminate in injuries to several organs, followed
by acute cardiac injury, edema, ARDS, changes in gas exchange,
secondary opportunistic infections, multi-organ failure and
death. That said, preventing or attenuating the development
of the cytokine cascade seems to be the way forward in the
treatment of COVID-19 infected patients (Atluri et al., 2020).
On the other hand, until an effective treatment is established, the
management of the pandemic essentially involves the control of
infections and the community transmission of the virus. The set
of strategies should include ensuring early diagnosis with effective
data sharing, isolation of the infected, maintenance of social
orders, quarantine, the fidelity of disseminated information,
and supportive treatments. For individuals, protective measures
like the improvement of personal hygiene measures, the use of
protective barriers such as masks, visors and gloves and the
guarantee of good ventilation in closed spaces, can effectively
reduce the transmission of the virus (Madabhavi et al., 2020).
In summary, COVID-19 is an unprecedented challenge for
clinicians because of the high transmission rate (Sun et al.,
2020a), making the number of cases classified as severe increasing
markedly worldwide while effective and precise treatments are
still absent. Efforts are being made in a global perspective to find
solutions or treatments (Zhai et al., 2020).
Cell-based therapies, particularly those involving MSCs or
their extracellular vesicles (EVs) and secretome, have recently
started to be used in the treatment of COVID-19 respiratory
disease (Khoury et al., 2020). MSCs are non-hematopoietic,
multipotent cells, able to differentiate into the three dermal
lineages, and are present in tissues of different sources, ranging
from fetal to many adult tissues. Due to their proven benefits
when used in Regenerative Medicine, MSCs are good options
for use as cell-based therapies in regenerating and replacing
injured tissues and organs, but their potential goes way beyond
that, with multiple therapeutic utilities and positive outcomes
with immunomodulatory and anti-inflammatory properties in
neurodegenerative, autoimmune, and cardiovascular diseases
(Ullah et al., 2015; Li and Hua, 2017; Denton et al., 2018;
Shammaa et al., 2020). While lodged in the lungs, the MSCs
can balance the inflammatory response and release mediators
including antimicrobial peptides, angiogenic growth factors, and
EVs (Khoury et al., 2020), presenting MSCs as an valuable
option to be used to treat COVID-19. As a matter of fact, MSCs
present immunomodulatory capacity, so, it is observed their
ability to prevent and attenuate the cytokine storm, reducing
the morbidity and mortality. This literature review aims at
discussing MSCs as a strategy for the medical approach of
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severe or critical COVID-19 patients and further understanding
the impact of MSCs origin and in vitro culture conditioning
methods, as well as their characterization, on their therapeutic
potential and clinical significance toward COVID-19 disease.
Recent clinical trials outcomes, with use of MSCs for COVID-
19 will be analyzed. It seems that expanded umbilical cord
mesenchymal stem cells (UC-MSCs) may be the most efficient
possible treatment available, associated to supportive therapies,
for severe clinical cases (Atluri et al., 2020; Xiao et al., 2020).
ORIGINS, DEVELOPMENT AND
CLINICAL APPLICATIONS OF
MESENCHYMAL STEM CELLS (MSCs)
Origins, Discovery and Brief Historical
Context of MSCs
Friedenstein was one of the pioneers in the study of stem cells
and the identification of multipotential stromal precursor cells.
Based on his 1960s and 1970s discoveries, it was shown that
mouse bone marrow (BM), like other blood-forming organs,
contained clonogenic progenitor cells that, once in culture,
could originate fibroblasts and other mesodermal cells. He also
understood that these cells were precursors of cartilage and
bone-forming cells but did not belong to the hematopoietic
cell lineage (Frieedenstein et al., 1968). From BM, Friedenstein
was also able to isolate adherent cells identical to fibroblasts
that grew rapidly in vitro and were able to form clonogenic
colonies called colony forming unit-fibroblast [CFU-F]. Cells
isolated from CFU-F had the additional ability to differentiate
into chondrocytes, osteocytes, osteoblasts and adipocytes in vitro
(Friedenstein et al., 1974). Arnold Caplan later called these cells
“Mesenchymal Stem Cells,” establishing similarities with stem
cells originating from mesodermal tissues at the embryonic level,
having been able to promote their growth from adult tissues
(Caplan, 2009). Haynesworth et al. (1992b) was able to grow
and expand BM-MSCs from the iliac crest’s BM collected in
human donors, revealing the human BM’s ability to produce
cells with the potential to grow in culture and with osteogenic
capacity. SH-2 and SH-3 were identified as specific cell surface
antigens on MSCs by the same group (Haynesworth et al., 1992a).
Subsequently, Barry et al. (2001) established CD105 and CD73 as
ligands corresponding to SH-2 and SH-3.
In the next years, massive interest in MSCs studies was
established and, even though BM was exploited as the source
organ of MSCs in the first place, quickly adult adipose tissue
(AT) was established as a main niche of MSCs, demonstrating
an equally interesting multipotency ex vivo (Gomez-Salazar
et al., 2020). The rapid interest that fell on MSCs, associated
with their demonstrated clinical relevance and some controversy
associated with the characteristics and nomenclature attributed,
raised the need to establish an official and more restricted
definition for these cells. The International Society for Cellular
Therapy (ISCT) in 2006 (Dominici et al., 2006), established
the parameters that were established as the four minimum
criteria that should be used to define cells as MSCs, which
were quickly accepted by the scientific community: (i) be plastic
adherent; (ii) expression of CD105, CD90, and CD73 cell surface
antigens; (iii) no expression of CD45, CD19, CD14 CD11b,
CD34, CD79a, and HLA-DR cell surface antigens; (vi) Capacity to
differentiate into adipocytes, chondrocytes and osteoblasts. MSCs
have been frequently re-baptized with various names such as
“Mesenchymal Progenitor Cells,” “Multipotent Adult Progenitor
Cells” or “Multipotent Adult Stem Cells” that diverged only
vaguely from the original definition. Other denomination such as
“Multipotential Stromal Cells” or “Mesenchymal Stromal Cells,”
even fitting in the MSCs acronym, are based on radical differences
in terms of biologic meaning (Gomez-Salazar et al., 2020). It
is true that MSCs share several characteristics with stem cells,
but some of their elements related to permanent cell lineage
repletion in vivo do not allow them to be considered as “true
stem cells” and require the use of a different denomination.
More recently, one work has established MSCs as natural
precursors for adventitial cells, perivascular fibroblasts and
pericytes, pointing to a stromal origin for MSCs (Crisan
et al., 2008). Although more recently the 2006 ISCT guidelines
have advised the use of the term “Multipotent Mesenchymal
Stromal Cells,” the original term “Mesenchymal Stem Cells”
continues to be mostly used. Finally, to highlight the fact
that the therapeutic action of these cells may be primarily
related with releasing growth factors and cytokines, Arnold
Caplan supported the use of the term “Medicinal Signaling
Cells” (Caplan, 2017). To simplify, to make everything uniform,
and facilitate bibliographic research, the term “Mesenchymal
Stem Cell” remains the most commonly used name. Recent
findings demonstrate that MSCs can be isolated from any
mesenchymal tissue or niche that manifests regenerative capacity,
and that these cells have basic Stem Cell capabilities such
as clonogenic potential, self-renewal, and ability to regenerate
tissues in vivo and multi-lineage differentiation capacity. Some
MSCs that are cultured in vitro lack specific identifying markers
(Lanza et al., 2009), so the variable expression level of these
markers could probably arise from differences between species,
tissue sources, and culture conditions that we will discuss
in this review. MSCs represent an important tool in the
development of new possible therapies with applications in
regenerative medicine, immunotherapy, tissue engineering, and
cell and molecular biology with almost 10,000 papers published
in the last 40 years [search, in the PUBMED.gov search
engine, by the term “(Mesenchymal stem cell) OR (MSCs),”
on 08/31/2020] and hundreds of clinical trials made over the
years, with more than 500 active trials currently (Figure 1)
(research, in the ClinicalTrials.gov database, under the terms
“MSCs,” on 08/31/2020).
Sources, Isolation, and Cultivation of
MSCs
Stem cells can be categorized considering their profile of
differentiation and source within the human body. Discovered
originally in the BM, this type of cells is still recognized as the
more promising for clinical application and research, although
some alternative sources including AT, birth-derived tissues,
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FIGURE 1 | A brief history of mesenchymal stem cells discovery and research.
amniotic fluid (AF) and placenta, dental pulp (DP), olfactory
tissues, synovium and synovial fluid, endometrium, muscle, and
peripheral blood — have since been identified, as we can see in
Figure 2 (Berebichez-Fridman and Montero-Olvera, 2018).
In theory, MSCs can be isolated from almost any tissue
in the human body. Despite this, it is necessary to consider
some practical limitations, such as the associated difficulty,
the degree of invasion of the collection method and the
characteristics of the donor himself. Parameters such as tissue
source, isolation technique and the culture medium used can
alter the properties of the collected human MSCs. MSCs can
differentiate in the neuroectodermic and endoderm lines, in
addition to the already known capacity for mesodermal lineage
differentiation (Mushahary et al., 2018). The developmental
origin of mesenchymal tissues, including not only mesoderm
but also the cranial neural crest, may be the explanation
for this ability. It is important to note that recently it
was demonstrated that MSCs are mostly derived from the
neural crest and neuroepithelium, even though traditionally it
was considered the mesodermal origin (Uccelli et al., 2008).
Embryonic Stem Cells (ESCs) are totipotent because they can
form both embryonic and extraembryonic structures. Moreover,
ESCs can proliferate indefinitely under specific culture conditions
and retain the capacity to differentiate into cell types from the
three embryonic germ layers. On the other hand, adult stem cells
are undifferentiated multipotent stem cells obtained from adult
individuals and differentiate into the cell types that constitute
their respective source tissue (Uccelli et al., 2008; Berebichez-
Fridman and Montero-Olvera, 2018).
Bone Marrow
The procedure to obtain BM-MSCs is a highly invasive and
can result in pain or infection, making the selection of other
sources, like peripheral blood or surgical remnants such as
AT, preferable (Berebichez-Fridman et al., 2017). The cell yield,
longevity, and potential for differentiation decrease with donor
age (Choudhery et al., 2014). About 0.01 and 0.001% of the
total nucleated cells isolated from BM aspirates are MSCs (Salem
and Thiemermann, 2010). Besides that, these cells continue to
be widely used, as they can be effortlessly isolated from a small
quantities of aspirate and have a short culture time, being able
to double 40 times its numbers in about 8–10 weeks of culture
(Salem and Thiemermann, 2010). In terms of differentiation,
BM-MSCs have an advantage when compared to other sources,
with high multi-lineage differentiation and proliferation capacity.
This type of stem cell is the most widely investigated, with
active studies in arterial hypertension, ischemic heart failure,
digestive system, treatment of spinal cord injuries, among
others, and therefore is considered to be the gold standard
(Choudhery et al., 2014).
Adipose Tissue
Adipose tissue is the second most reputable source of MSCs,
with an estimated 98–100% cell viability. The morphological,
phenotypical, and functional characteristics of AT-MSCs are
similar to BM-MSCs (Choudhery et al., 2014). Besides their
stability in long-term cell cultures, AT-MSCs can expand
effectively in vitro and possess high multi-lineage differentiation
potential. AT is a more advantageous autologous niche of MSCs
for tissue engineering than BM (Choudhery et al., 2014). Its main
advantage as a MSCs source is convenience, as human AT is
usually abundant throughout the body and is easily accessible
through liposuction procedures.
Birth-Derived Tissues
Currently, umbilical cord blood (UCB) is accepted as a
source of hematopoietic stem cells, but also of MSCs and the
abundance of UCB, availability of donors, facility of acquisition,
and reliability of sample collection are relevant advantages
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FIGURE 2 | Adult and fetal tissue sources (niches) of MSCs in the body (modified from Servier Medical Art, licensed under a Creative Common Attribution 3.0
Generic Licence. https://smart.servier.com/).
(Berebichez-Fridman and Montero-Olvera, 2018). UCB-MSCs
are more immature than other types of adult stem cells, and do
not evoke a strong immune rejection response in an allogeneic
recipient. UCB-MSCs can be cryopreserved in vast quantities
for later cultivation and research, but also for the treatment of
hematologic pathologies, and possess osteogenic, chondrogenic,
adipogenic, and myogenic differentiation potential. Lately,
Wharton’s Jelly (WJ) has gained attention as an excellent
source of MSCs, as these MSCs present immuno-privileged and
immunomodulatory phenotype (Caseiro et al., 2015).
Amniotic Fluid and Placenta
The phenotype of cultured cells collected from AF is similar to
that of BM-MSCs. Cultured cells obtained from this source can
differentiate into mesenchymal lineages, with a high self-renewal
capacity and a doubling time of 36 h, maintaining a normal
karyotype even at late passages. Placenta-derived MSCs also
express embryonic stem cell markers and can differentiate
into mesenchymal as well as hepatic, pancreatic, and neuronal
lineages (Spitzhorn et al., 2017).
Mobilized Peripheral Blood
Peripheral blood stem cells may be mobilized from healthy
donors using granulocyte-macrophage colony-stimulating
factor (GM-CSF). The underlying mechanism involves several
adhesion molecules that facilitate the binding of stem cells
to BM and their disruption allows for their release into the
circulation. A large volume of blood and, therefore, a higher
quantity of MSCs can be collected compared to BM-MSCs
(Pouryazdanpanah et al., 2018).
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Synovium and Synovial Fluid
In humans, cartilage and synovium originate from a common
pool of cells during synovial joint development. Synovia-
derived MSCs are far superior to cells derived from the
skeletal muscle and AT, as determined by their in vitro
expandability, differentiation potential, and epitope profiles
(Berebichez-Fridman and Montero-Olvera, 2018). Their superior
chondrogenic and proliferation potential has been reported
by several groups, making these cells fair candidates for
cell therapy applications, particularly regarding osteoarticular
disorders (Branquinho et al., 2012).
Dental Pulp
DP-derived MSCs specialize in odontoblasts, which produce
dentin. These cells are obtained from pulp tissue and the
periodontal ligament, and are extracted by an enzymatic digestive
process or explant method. DP-MSCs are easy to cryopreserve
and, similarly to AT-MSCs, possess immunomodulatory
properties. In addition to differentiating into osteo/chondroblasts
and adipocytes, DP-MSCs can also differentiate into neuronal
lineages (Caseiro et al., 2019).
Olfactory Tissues
The lamina propria of the olfactory mucosa is the niche for
olfactory mucosa mesenchymal stem/stromal cells (OM-MSCs)
that are derived from the neural crest. Different works involving
OM-MSCs revealed its fibroblastic-like cytomorphology,
development of low density colonies, the plastic-adhesion, the
expression of expected surface markers and also the capacity
for differentiation, not only the classic tri-differentiation but
also other pathways such as neuroglial and myogenic (Alvites
et al., 2020a). Its secretome has also started to be analyzed,
and it was possible to identify several bioactive molecules with
pro-regenerative and immunomodulatory functions (Ge et al.,
2016). The clinical use of these cells can be advantageous due to
their anatomical location, easily accessible, and also to their wide
distribution in the nasal cavity. Additionally, previous studies
have already shown that OM-MSCs can be maintained in culture
for extended periods without chromosomal or tumorigenic
changes being observed. This capacity, affected by the donor’s
age, seems to be related with some inhibiting of apoptotic
activity and conservation of telomeric activity (Alvites et al.,
2020a). OM-MSCs have already been isolated from the olfactory
mucosa of several species (Veron et al., 2018), including humans
(Delorme et al., 2010), and their therapeutic effectiveness has
also been tested with promising results in neurodegenerative
diseases of the central nervous system, peripheral nerve injuries,
autoimmune diseases and even myocardial tissue injuries
(Alvites et al., 2020b).
Isolation and Cultivation
Mesenchymal stem cells are plastic-adherent cell populations,
isolated through procedures involving tissue mincing, enzymatic
digestion, and cell growth on a plastic surface. The two
main procedures are the enzymatic and explant protocols
(Mushahary et al., 2018). In the explant method, one of
the earliest techniques applied, the tissue is rinsed with a
saline solution and mechanically split into smaller fragments.
Fragments are further placed on a culture dish and covered
in adequate culture medium. After some days in culture,
MSCs start outgrowing from the explants’ limits, and as they
reach total confluence, explants can be carefully detached.
The enzymatic method entails a more complex protocol. After
rinsing with a saline solution and mechanical splitting into
smaller fragments, identically to the first steps on the explant
method, the tissue is incubated with an enzymatic solution.
As a result, singe cells or aggregates are released and remain
suspended in the enzymatic solution. After centrifugation for
elimination of the enzymatic solution, the cell pellet is re-
suspended in adequate culture medium and seeded in culture
dishes. MSCs therapeutic potential toward a specific tissue
regeneration lies not only on the MSCs tissue of origin, but also
on their potential itself and on their secretion potential of bio-
factors with pharmacological properties, the so called secretome.
MSCs protocols between groups regarding isolation, culture
conditions and characterization varies immensely, impairing
the reproductivity of results between different research groups.
A critical parameter when considering MSCs is the cell potential
toward regeneration. It has been reported to be influenced by
cell passage number/age, and cryopreservation/defrosting cycle-
related injury (Rendra et al., 2020). An improved therapeutic
efficacy of MSCs is greatly influenced by optimized culture
condition protocols (Alvites et al., 2020a).
Characterization and Phenotype of
MSCs
As previously mentioned, in 2006 the ISCT proposed four
minimum criteria to characterize cells as MSCs for research
purposes (Dominici et al., 2006): be plastic-adherent in standard
culture conditions (Dominici et al., 2006). Second, the MSC
population must express CD105 (known as endoglin, first
known as SH-2), CD73 (known as ecto 5’ nucleotidase,
first identified as SH-3), and CD90 (also known as Thy-1),
and lack expression of CD45 (pan-leukocyte marker), CD34
(hematopoietic progenitors and endothelial cells marker), CD14
or CD11b (expressed on monocytes and macrophages), CD79a or
CD19 (markers of B cells) and HLA class II. Lastly, MSCs most
be able to differentiate into three different lineages: osteoblasts,
adipocytes and chondroblasts. It’s crucial to know that these
identifying criteria should not be confused by no means and
does not represent adequate criteria and characteristics for
MSCs used therapeutically and in clinical studies because the
proposal is meant only to describe identifying criteria for
research purposes. The homogeneity of these characteristics
is relative as different MSCs population express different
surface markers, an understandable feature, as MSCs present
plasticity, a dynamic capacity to adapt and vary over time to
different conditions. Different antigen sets are applied from
different research groups, to characterize these cells, with
different outcomes, thus, no specific marker was identified as
to uniquely characterize MSCs. MSCs can differentiate into
different cell types when an array of differentiation factors is
used to mimic osteogenic, chondrogenic, or adipogenic in vitro
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microenvironment, for instance. Standardized procedures for
culture conditions and MSCs characterization still remains a
major challenge. Although the official criteria speak of tri-
differentiation, it has long been known that MSCs can follow
multiple types of differentiation and that is also a factor in the
discussion of these criteria, with some studies suggesting the
addition of other criteria factors for MSCs characterization. Some
research groups suggest that to profile MSCs we must observe key
parameters like CFU-F efficiency, MSC isolation, multilineage
differentiation, immunomodulation, telomere length, trophic
factor quantification, cumulative growth, and surface phenotype
(Samsonraj et al., 2017). However, the ISCT guidelines are still the
recommended criteria for the isolation and characterization of
MSCs and are precise enough to combine the majority of the to-
day existing knowledge, recognizing that future research, along
with scientific breakthroughs, will probably lead to optimization
of the criteria (Greif et al., 2020; Kurenkova et al., 2020).
Multipotency Analysis of MSCs
Considering MSCs are an interesting source for autologous
transplantation and analysis of their cellular and molecular
pathway has been performed, as well as the niche changes,
as to assess on the cytokines, chemokines and other bioactive
factors role in the differentiation potential of these cells (Alvites
et al., 2020b). MSCs present a great differentiation potential
toward mesenchymal lineages. Under specific in vitro inducing
conditions, they can differentiate into adipogenic, osteogenic, or
chondrogenic lineage. Differentiation can be induced in vitro,
when seeding MSCs in specific differentiation supplemented
media, as shown in Figure 3.
Regarding differentiation into the adipogenic lineage,
supplementation includes dexamethasone, indomethacin,
insulin, and isobutylmethylxanthine. As for the chondrogenic
lineage, the cells can be cultured in Dulbecco’s modified Eagle’s
medium supplemented with insulin, transferrin, selenium,
linoleic acid, selenium acid, pyruvate, ascorbic phosphate,
dexamethasone, and TGF-β III, and optionally IGF-1 and
bone morphogenetic proteins-2. The osteogeneic lineage
differentiation includes supplementation with of ascorbic
acid, β-glycerophosphate, and dexamethasone (Mushahary
et al., 2018). The differentiation into these three lineages is
evaluated as for the presence of fat droplets (adipogenesis),
proteoglycans and type II collagen synthesis (chondrogenesis),
or mineralization of calcium deposits and increase in alkaline
phosphatase expression (osteogenesis) (Sami et al., 2016). MSCs
can differentiate into other lineages, such as the neurogenic,
myogenic, tenogenic, and others as it was previously reported
by several research groups (Branquinho et al., 2012; Ge et al.,
2016). For instance, a process defined as mesengenesis has been
reported by Caplan (1994), where MSCs originated myoblasts,
ligaments, tendons and other cell types (Sami et al., 2016). Ever
since, MSCs have been reported to originate cells from the
heart, peripheral blood, cord blood, muscle, AT, lung, trabecular
bone, intestine, kidney, liver, pancreas, synovium, skin, and
even in the brain (Mushahary et al., 2018), being described
as multipotent cells that representing a promising source for
Regenerative Medicine.
Clinical Significance of MSCs Therapy
The discovery of MSCs and their properties has increased the
interest in deepening knowledge over their therapeutic features.
MSCs are an excellent candidate for cell therapy since they are
easily accessible – tissue collection and isolation are relatively
simple, and proliferate in vitro. MSCs are easily preserved,
maintaining their potential, and clinical trials have been showing
promising results (Andrzejewska et al., 2019). Firstly studied
because of their potential in Regenerative Medicine, other
mechanisms of action have been studied and investigated
in different areas like immunomodulation and inflammatory
process, as well as the paracrine effects of MSC secretome
(Caseiro et al., 2019). The attention is now focused on the
secretome and EVs as candidates to explain the therapeutic effects
of MSCs (An et al., 2020; d’Angelo et al., 2020; Varderidou-
Minasian and Lorenowicz, 2020).
Mesenchymal stem cells therapeutic potential toward
restauration of tissue function is associated with three different,
but complementary, mechanisms. “Homing” is the term used to
describe their aptitude to migrate toward the lesion site, due to
chemotactic mechanisms, mediated by integrins and selectins.
The second mechanisms, as described before, is the multi-lineage
differentiation capacity, promoting cell engraftment and tissue
regeneration (Caplan and Dennis, 2006). The third mechanism
entails the secretion of bioactive factors, modulating both local
and systemic physiological processes (Biju and Jack, 2013). In
animal models, there are several registered successful clinical
trials with promising results in several different tissues like
myocardial, renal, hepatic, neuronal, among others (Shammaa
et al., 2020). Therefore, the regenerative properties of MSCs
are the main feature studied, with a focus on degenerative
conditions that are widely exploited. The most recent approaches
in regenerative medicine employ scaffolds (Pedrosa et al., 2017;
Vizoso et al., 2017) or MSC engineering on both genetic and
architectural levels (Shammaa et al., 2020).
Apart from their tissue regeneration potential, MSCs
have been described as modulators of the immune system,
attenuating tissue impairment due to inflammatory processes.
The modulation of the immune system by the MSCs is mediated
by the secretion of soluble factors and direct contact with
immune cells. Studies have reported MSCs interaction and
suppression of immune cells, native and adaptive (Alvites
et al., 2020a). MSCs also induce regulatory T cells and suppress
self-reactive T-effector responses (Pedrosa et al., 2017). The
ability to modulate the immune system by cell contact has been
investigated, and it is specially of benefit when considering
autoimmune conditions and neurodegenerative disorders
(Shammaa et al., 2020).
Secretome and Conditioned Media as a
New Therapeutic Strategy
The secretome is defined as substances, factors/molecules
secreted by the cells to the extracellular matrix, a promising
mechanism considering regenerative cell based-therapies and
cellular mechanisms. The secretome includes soluble proteins,
free nuclei acids, lipids, EVs among others. The use of cell-free
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FIGURE 3 | Differentiation potential and the mesengenic process (modified from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic
Licence. https://smart.servier.com/).
therapies, using, for example, the conditioned media as a
source of MSCs’ secretome, reveals several benefits such as
safety, once that the application of the secretome resolves
potential impairments as immune compatibility, tumorigenicity,
emboli formation and the transmission of infections. It
has other advantages like the storage without potentially
toxic cryoprotectors, it is more economic and the time of
expansion and maintenance can be considerably reduced. MSCs’
secretome has diverse mechanisms and great potential in
immunomodulation, anti-apoptotic activity, wound healing and
tissue repair, neuroprotective effect, angiogenesis regulation,
antimicrobial effect, and antitumor effect (Caseiro et al., 2019;
Alvites et al., 2020a). EVs, elements of the MSCs secretome,
deserve a specific mention due to the recently accelerated studies
of its clinical applications. EVs are exosomes, microvesicles and
apoptotic bodies, that transport biologically active molecules and
genetic information to target cells, thus affecting their potential
and function (Trohatou and Roubelakis, 2017).
MSCs AS A POTENTIAL THERAPY FOR
COVID-19
According to the WHO, the control of COVID-19 has
mainly directed on infection prevention, case detection, and
monitoring, since the currently approved treatments are of
support and not directly envisioning the cure of the pathology.
Although vaccines are being developed in order to reduce the
infection rate of COVID-19, a developing demand to cure the
increasing number of patients who develop pneumonia and
other critical symptoms is emerging. That’s where MSCs can
have a crucial role, by minimizing the symptoms of COVID-
19 and giving a chance to the patient immune system to
act against the virus and promote the pulmonary parenchyma
regeneration (WHO, 2020).
As previously reported, the most clinical used MSCs are
the ones obtained from the autologous BM. The other MSCs
available for clinical application are the ones from the adipose
tissue, umbilical cord tissue and blood, amniotic membrane
and dental pulp (Atluri et al., 2020). According to recent
publications and by consulting the site www.clinicaltrials.gov,
the umbilical cord is the most adequate source for MSCs,
for several reasons: (i) high concentration of MSCs, (ii) UC-
MSCs can be obtained during or after birth, by non-invasive
techniques, (iii) the Wharton-jelly is considered a by-product,
and several high quality samples are cryopreserved around
the world in public and private high-regulated banks; (iv)
UC-MSCs present faster doubling times, since these cells
are closer to embryonic-stem-cells (ESCs) when compared
to bone-marrow or adipose tissue MSCs; (v) on the other
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hand the UC-MSCs are safer than ESCs because are not
tumorigenic; (vi) can be used as an allogenic treatment since
these cells are immunoevasive and express low levels of major
histocompatibility complex (MHC) class 1 molecules and no
MHC class II (Caseiro et al., 2015, 2019). The intravenous
administration is the selected route for the treatment with UC-
MSCs, since most of the infused UC-MSCs will be trapped
in the lungs, the most affected organ in COVID-19 patients
(Wang et al., 2020).
As an important cell population, MSCs have the potential
to conduct to very promising outcomes, when considered for
the treatment of lung disease. The regulation of the immune
system in the lung, by these cells, entails modulation of
activation and effector function of immune cells, suppressing of
infiltrated cells and diminishing edema (Liu et al., 2020). MSCs
have been reported to efficiently cure ALI/ARDS, principally
by paracrine mechanisms based on the action of EVs, such
as microvesicles and exosomes (Chan et al., 2015). In vitro
studies reported that UC-MSC demonstrated therapeutic efficacy
on mice with ALI induced by influenza A (H5N1) virus.
Researchers confirmed that UC-MSCs presented effective results
for the restoration of damaged alveolar fluid clearance and
protein permeability of influenza A infected alveolar epithelial
cells (Fujita et al., 2018). Clinical studies made in patients
with Influenza H7N9 virus, which presented symptoms such
as ARDS, lung failure, and fulminant pneumonia, showed
that MSCs are a promising choice for treating virus-induced
pneumonia. Based on informed consent, 44 patients with
H7N9 induced ARDS were included as the control group,
while 17 patients with H7N9 induced ARDS served as the
experimental group, injected with allogeneic menstrual blood-
derived MSCs. The transplantation of MSCs significantly lowered
the mortality rate compared with the control group, with
no adverse effects. The results suggest MSCs improved the
survival rate. Once Influenza A and COVID-19 share analogous
symptoms (such as ARDS and lung failure) and similar multi-
organ dysfunction, along with the positive results of in vitro
tests and clinical studies, MSCs-based therapy are considered
a promising therapeutic alternative for treating COVID-19
(Khatri et al., 2018).
MSCs as a Treatment for COVID-19
To date, there is limited published information regarding
COVID-19 disease and the potential efficacy of MSCs, although
MSCs efficacy in influenza lung infections has been recently
reported. MSCs can affect the performance of immune cells,
both adaptive and innate, and therefore, MSCs therapy can
theoretically inhibit the over-triggering of the immune system
and promoting endogenous repair following SARS-CoV-2
infection. Several countries have begun clinical studies on MSCs
therapies, and some positive results have been published. A study
reported from China, on a 65-year-old female patient with a
critical condition of COVID-19 presented promising outcomes
after 21 days of treatment with UCB-MSCs. Initially, the patient
showed neutrophil increase and lymphocyte decreased, and was
treated with several antiviral drugs, while being subjected to non-
invasive mechanical ventilation. As the vital signs deteriorated,
the patient received 3 doses of single UCB-MSCs solution. The
vital signs improved after the second MSCs administration as
other symptoms gradually disappeared. Following, the patient
was removed from the ventilator, with a normal number
of immune system blood cells. The results suggested UCB-
MSCs to be an alternative and effective treatment option for
patients suffering with COVID-19, alone or in combination
with other existing therapies (Chen et al., 2020). A different
group in China of 7 patients with COVID-19 were selected,
one with critical diagnosis, 4 with severe diagnosis, and 2
showing moderate symptoms. Three additional patients with
severe diagnoses were chosen as placebo control. All patients
presented pyrexia, breath impairment, and thus low oxygenation
rates, and pneumonia. As the patients’ health status was
aggravating, 1 million MSCs per kilogram body weight were
administered. Patients were kept on observation during 2 weeks
recovery period. Mitigation of the symptoms was observed 2–
4 days after treatment, along with a decrease in pneumonia
infiltration, with no apparent adverse effects. This study as
the one previously described, demonstrated MSCs intravenous
infusion as a safe and efficient therapeutic alternative for
treating COVID-19 patients (Golchin et al., 2020). As mention
before, as the immune system is over-triggered it leads to
a cytokine storm. The cytokine storm is one of the worst
consequences of the disease with the production of inflammatory
cytokine accompanied by a weak interferon response. Notably,
SARS-CoV-2 triggers pathogenic Th1 cells into secreting pro-
inflammatory cytokines, as GM-CSF and interleukin-6 (IL-6).
Furthermore GM-CSF activates CD14+CD16+ inflammatory
monocytes into producing extensively IL-6, TNF-α. Thus, The
COVID-19 consequent cytokine-storm constitutes on a large
expression of IL-6 and TNF-α, but recent investigations also
showed that high levels of IFN-y, interleukin (IL)- 1β, 2, 4, 6,
8, 10, 17, induced protein 10 (IP10), monocyte chemoattractant
protein-1 (MCP-1), are also significantly elevated in patients
with severe COVID-19 (Hu et al., 2020). Both studies presented
before, included patients with those characteristics. However,
the immunomodulation capacity of MSCs was the key to
the promising results obtained and transplantation of MSCs
also presented excellent outcomes. Suppressing over-triggering
of the immune system and enhancing of the endogenous
microenvironment repair capacity are some of the potential of
MSCs therapies. Their particular immunomodulation potential
results in reduced concentration levels in pro-inflammatory
cytokines and chemokines in the patients’ serum. MSCs
regulatory capacity also includes increased dendritic cells
migrating to the injured tissue, as well as a minor migration
of mononuclear/macrophages migration to the lesion site,
resulting in a decrease of the levels of reactive C-protein (a
biomarker for inflammation), a rise in oxygen saturation and
improvement of lymphopenia (low level of lymphocytes in the
blood). Moreover, the increase of IL-10 modulated the immune
system and Vascular Endothelial Growth Factor (VEGF) also
promoted angiogenesis conducting to lung repair. MSCs can
release VEGF but also hepatocyte growth factor (HGF), which
are able to stabilize endothelial barrier function by restoring
pulmonary capillary permeability. By inhibiting pulmonary
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vascular endothelial cell apoptosis, enhancing the recovery of VE
cadherin, and reducing pro-inflammatory factors, MSCs control
inflammation and protect the lung endothelial barrier (Wang
et al., 2020). In both studies intravenous infusion was applied,
and it seems to be the most beneficial route of administration
due to the fact that, some MSCs concentrate in the lung
tissue, after intravenous infusion. Intuitively, this should likely
be beneficial and enhance the pulmonary microenvironment
recovery, protecting alveolar epithelial cells, preventing fibrotic
tissue formation, thus improving pulmonary function (Bulut
and Kato, 2020; Madabhavi et al., 2020). Those clinical trials
also investigated if SARS-CoV-2 could infect the MSCs used,
through the ACE-2 receptor widely distributed on human cells,
but the MSCs that were initially negative, remained ACE-2
negative and free from COVID-19. The positive results of those
two studies are thought to be related to immunomodulatory
properties of MSCs as well as MSCs differentiation potential that
can avoid lung tissue impairment, by blocking the cytokine storm
and by promoting regenerative and reconstructive processes on
the affected tissue. Furthermore, MSCs secretion of paracrine
factors, and their interaction with immune cells, leads to
immunomodulation and a robust anti-inflammatory activity
(Chan et al., 2015).
Future Challenges and Perspectives
Given the urgent need to find out an effective treatment, there
are 3567 active clinical trials concerning COVID-19 at the
date of October 1, 2020, involving several different approaches,
several mechanisms of action, biomolecules and drugs. Knowing
the potential of MSCs, and based on positive results already
obtained, several clinical trials using MSCs have already began
or are outlined to start shortly. Searching the words “COVID-
19” and “Mesenchymal Stem Cells” is possible to identify 62
active trials. Of the 62 trials, 16 are located in the American
continent, 9 are located in Europe, 11 in East Asia, and the other
26 are distributed over the remaining continents. Considering
the different origins of MSCs, 17 of the clinical trials use
UC-MSCs, 9 assays use AT-MSCs, 6 use BM-MCs, 5 use WJ-
MSCs, 2 use DP-MSCs, 1 uses OM-MSCs, 1 uses MSCs derived
exosomes, and 21 clinical trials do not specify concretely the
source, or use more than one. Notably, 57 of the clinical trials
are in Phase 1 or Phase 2, research phases to describe and
collect preliminary data on the drug performance in people
suffering with the disease, and 3 clinical trials are already
in Phase 3, a phase of research that collects information on
the pharmaceutical safety and effectiveness, analyzing diverse
populations, dosages and application of the drug combined with
others (research, in the ClinicalTrials.gov database, under the
terms “MSCs,” on 10/1/2020).
CONCLUSION
The current pandemic we are facing, that has not yet shown
signs of weakening, is one of the great scourges of recent years
and considering the need for mitigation, envisioning at keeping
mortality rates low, there is an urgent need to discover effective
mechanisms of prevention and therapies. Global efforts are
focused on research and development of new therapies, testing
different approaches, where MSCs based-therapies standing out.
Regarding the pathogenesis of the SARS-CoV-2, several groups
reported an initial recognition of the ACE-2 receptor. These
are cell-membrane receptors, widely distributed, and particularly
in alveolar cells. In addition to the mild symptoms as fever,
cough, muscular soreness, expectoration, and dyspnea, COVID-
19 can trigger an immune system overreaction, causing a
cytokine storm followed by edema, inefficient gas exchange,
ARDS, cardiac impairment, and secondary infection that can
lead to death. The currently available cure of the COVID-19
disease is mainly dependent on the immune system function
of the patient, therefore, avoiding cytokine overproduction
may be decisive to recovery of SARS-CoV-2 patients. Current
evidence suggests that therapies applying MSCs and MSCs
secretome/EVs are a safe and an efficient approach for treating
patients suffering from COVID-19 induced pneumonia, with
the possibility to reverse severe critical disease with high
potency, without the occurrence of severe adverse events.
The immunomodulatory properties of MSCs can prevent lung
tissue impairment by inhibiting pro-inflammatory cytokines
overproduction and by promoting regeneration of the damaged
tissue, as MSCs secrete a variety of paracrine factors, responsible
for their immunomodulation and anti-inflammatory properties.
Stem cell therapy, especially MSCs can potentially be an ideal
therapy or be part of a combination of therapies to treat
COVID-19 patients, nonetheless, since the number of patients
who underwent this kind of treatment is still restricted, more
studies with larger samples are needed to validate this therapeutic
option, to comprehend the SARS-CoV-2 mechanism of action
and to optimize this therapeutic option, by applying randomized
studies promoting safety and efficacy of MSCs application on
COVID-19 disease.
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